Business of Biotech Shorts

  1. Ep. 252, Chapter 2: Commercializing RNAi with Tolga Tanguler 7/8/2025

    Tanguler explains how the unique opportunities presented by commercial RNAi drugs can overcome physician skepticism and poor patient adherence. RNAi therapies like Alnylam Pharmaceuticals’ Leqvio (a quarterly subcutaneous injection for hypercholesterolemia) and the experimental Zilebesiran (a semi-annual injection for hypertension) offer high adherence rates (90-95%) due to their infrequent, convenient administration. Additionally, RNAi drugs fit within existing reimbursement structures.

  2. Ep. 252, Chapter 1: Tolga Tanguler & Alnylam 7/8/2025

    Chief Editor of Life Science Leader and Host of The Business of Biotech, Ben Comer, and Tolga Tanguler, EVP and CCO and at Alnylam Pharmaceuticals, discuss Tanguler’s career path from Merck and Pfizer to Alnylam Pharmaceuticals, an innovator in the RNA interference (RNAi) therapeutic space. Tanguler details how early work in a stigmatic disease area, followed by his son’s childhood leukemia diagnosis, shaped his approach to science and medicine.